Skip to content

Intravenous Lidocaine Infusion During Video-assisted Thoracic Procedures for Improved Pain Control

Intravenous Lidocaine Infusion During VATS Procedures Reduces Postoperative Analgesic Requirements

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01277835
Enrollment
48
Registered
2011-01-17
Start date
2010-02-28
Completion date
2013-02-28
Last updated
2014-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

video-assisted, thoracic surgery, VATS, lidocaine infusion, VATS procedures

Brief summary

The purpose of this study is to determine whether intravenous lidocaine infusion during a video-assisted chest surgery is effective in reducing the pain involved after the surgery. The hypothesis is that continuous lidocaine infusion during video-assisted thoracoscopic surgery (VATS) reduces morphine consumption and postoperative pain.

Detailed description

Despite newer surgical techniques, many patients still experience moderate to severe postoperative pain after minimally invasive surgeries. Thoracoscopic surgeries are often associated with severe postoperative pain. To relieve the pain, potent narcotics have to be used, which have many side effects. Surgical patients would therefore benefit from an intra-operative analgesic regimen that is safe and effective, has minimal side effects and can reduce their postoperative narcotic requirements. Intravenous lidocaine has been shown previously to relieve cancer pain, chronic pain, and pain after other types of surgery.

Interventions

DRUGLidocaine Infusion

Infusion of lidocaine 3mg/min or 2mg/min during surgery

DRUGPlacebo

Saline Infusion at same rate as experimental arm

Sponsors

University of Saskatchewan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* ASA I-III * Age 18-75 * Scheduled for VATS procedure

Exclusion criteria

* Patients receiving antiarrhythmic therapy (Class Ia, Ib, Ic) within one week of surgery * Patients on preoperative analgesic therapy within one week of surgery * Patients with history of drug or alcohol abuse * Patients who are allergic to lidocaine * Contraindication to self administered morphine (unable to understand the PCA) * Progression of the procedure to thoracotomy * Patients who need postoperative mechanical ventilation * Necessary major deviation from the intraoperative study protocol as per the discretion of the anesthesiologist in charge of the case * Patients who are breastfeeding or pregnant * Patient refusal

Design outcomes

Primary

MeasureTime frameDescription
Verbal Rating Scale for pain with deep inspirationUp to 48 hrs post-initiation of patient-controlled analgesiaPatients will be questioned about pain intensities with a deep inspiratory breath using the Verbal Rating Scale (0-10) at 8, 16, 24, 36, and 48 hours post-initiaition of patient-controlled analgesia.
PCA Morphine ConsumptionUp to 48hrs post-initiation of patient-controlled analgesiaPatient-controlled analgesia machines will be reviewed for the total morphine doses administered at 8, 16, 24, 36, 48 hours post-initiation of patient-controlled analgesia.
Number of PCA Morphine RequestsUp to 48hrs post-initiation of patient-controlled analgesiaPCA machines will be reviewed for total number of PCA requests at 8, 16, 24, 36, 48 hours post-initiation of patient-controlled analgesia.
Verbal Rating Scale for pain at restUp to 48hrs post-initiation of patient-controlled analgesiaPatients will be questioned about pain intensities at rest using the Verbal Rating Scale (0-10) at 8, 16, 24, 36, 48 hours post-initiation of patient-controlled analgesia.

Secondary

MeasureTime frameDescription
NauseaUp to 48hrs post-initiation of patient-controlled analgesiaPatients will be questioned about the side effect of nausea at 8, 16, 24, 36, 48 hrs post-initiation of patient-controlled analgesia.
Urinary RetentionUp to 48hrs post-initiation of patient-controlled analgesiaPatients will be questioned about the side effect of urinary retention at 8, 16, 24, 36, 48 hrs post-initiation of patient-controlled analgesia.
VomitingUp to 48hrs post-initiation of patient-controlled analgesiaPatients will be questioned about the side effect of vomiting at 8, 16, 24, 36, 48 hrs post-initiation of patient-controlled analgesia.
PruritusUp to 48hrs post-initiation of patient-controlled analgesiaPatients will be questioned about the side effect of pruritus at 8, 16, 24, 36, 48 hrs post-initiation of patient-controlled analgesia.
ConstipationUp to 48hrs post-initiation of patient-controlled analgesiaPatients will be questioned about the side effect of constipation at 8, 16, 24, 36, 48 hrs post-initiation of patient-controlled analgesia.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026